Meta-Analysis of Oxidative Stress in Schizophrenia

Joshua Flatow, Peter Buckley, and Brian J. Miller

Background: Schizophrenia is associated with impaired antioxidant defense, including abnormal serum, plasma, and red blood cell (RBC) oxidative stress parameters. We performed a meta-analysis of these associations, considering the effect of clinical status and antipsychotic treatment after an acute exacerbation of psychosis.

Methods: We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information, and the reference lists of identified studies.

Results: Forty-four studies met the inclusion criteria. Total antioxidant status seemed to be a state marker, because levels were significantly decreased in cross-sectional studies of serum and plasma in first-episode psychosis (FEP) and significantly increased in longitudinal studies of antipsychotic treatment for acute exacerbations of psychosis (p < .01 for each). The RBC catalase and plasma nitrite seemed to be state-related markers, because levels in cross-sectional studies were significantly decreased in FEP (p < .01) and significantly increased in stable outpatients (p = .01). In contrast, RBC superoxide dismutase seemed to be a trait marker for schizophrenia, because levels in cross-sectional studies were significantly decreased in acutely relapsed inpatients, FEP, and stable outpatients (p < .01 for each).

Conclusions: Oxidative stress abnormalities in FEP suggest an effect that might be independent of antipsychotic medications. Although some parameters (total antioxidant status, RBC catalase, and plasma nitrite) might be state markers for acute exacerbations of psychosis, others (RBC superoxide dismutase) might be trait markers; however, more longitudinal studies are needed. Our findings suggest that oxidative stress might serve as a potential biomarker in the etiopathophysiology and clinical course of schizophrenia.

Key Words: Antioxidants, first-episode psychosis, meta-analysis, oxidative stress, relapse, schizophrenia

Schizophrenia is a heterogeneous disorder with respect to symptomatology, disease course, and outcome (1). The clinical course is often characterized by recurrent relapses, which are associated with adverse outcomes including treatment-resistant symptoms, cognitive decline, and functional disability. Abnormalities involving antioxidant defenses in schizophrenia have been an enduring finding, with associations across different patient samples, study methodologies, and assay technologies. Despite the inherent complexity of this area of research, with significant heterogeneity in results and negative studies, a constellation of key findings support an association between oxidative stress and the pathophysiology of schizophrenia. Genes involving antioxidant defenses are associated with increased risk of schizophrenia (2). Abnormal oxidative stress parameters have been reported in peripheral blood (3), red blood cells (RBCs) (4), neutrophils (5), platelets (6), cerebrospinal fluid (7), and postmortem brain (8) in patients with schizophrenia. With proton magnetic resonance spectroscopy (MRS), previous studies found correlations between frontal lobe membrane phospholipid metabolism and cerebral morphology (9) and decreased in vivo glutathione (GSH) levels in the medial prefrontal cortex of patients with schizophrenia (7). A recent metabolic study found disturbances in antioxidant defenses in unmedicated patients with schizophrenia that partially normalized after antipsychotic therapy (10).

From the Medical College of Georgia (JF, PB); and the Department of Psychiatry and Health Behavior (BJM); Georgia Regents University, Augusta, Georgia.

Address correspondence to Brian Miller, M.D., Ph.D., M.P.H., Department of Psychiatry and Health Behavior, Georgia Regents University, 997 Saint Sebastian Way, Augusta, Georgia 30912; E-mail: brmiller@gru.edu.

Received Oct 8, 2012; revised Mar 20, 2013; accepted Mar 22, 2013.

Clinical trials also support an association between oxidative stress and schizophrenia. Several studies have found that antioxidants—including vitamin E (11), piracetam (12), and melatonin (13)—might improve symptoms of tardive dyskinesia in schizophrenia, although there are failures to replicate. A randomized, double-blind trial found that adjunctive treatment with the antioxidant N-acetylcysteine significantly reduced psychopathology in schizophrenia (14). Fish oil (long-chain omega-3 polyunsaturated fatty acids [PUFAs]) is a commonly used supplement in the general population aimed at reducing oxidative stress, although its benefits for prevention of cardiovascular disease (15) and cognitive decline (16) are not established. However, an important study found that supplementation with fish oil significantly reduced the progression to first-episode psychosis (FEP) in subjects with prodromal symptoms (17). These findings suggest that oxidative stress levels might be a biomarker of schizophrenia risk and response to adjunctive antioxidant treatment.

Oxidative stress refers to an imbalance of free radicals, such as reactive oxygen and nitrogen species, which are generated from both normal metabolism—including neurotransmitters associated with schizophrenia such as dopamine and glutamate—and from various environmental exposures. The failure of antioxidant defenses to protect against free-radical generation damages cell membranes, with resulting dysfunction that might impact on neurotransmission and, ultimately, symptomatology in schizophrenia (18). Important free radicals in humans include hydrogen peroxide, the hydroxyl radical, nitric oxide (NO), and the superoxide radical. In the rate-limiting step of purine catabolism, xanthine oxidase catalyzes the conversion of xanthine to uric acid, an important antioxidant, and also generates superoxide radicals. Superoxide dismutase (SOD) catalyzes the conversion of superoxide radicals to hydrogen peroxide. Both catalase (CAT) and glutathione peroxidase (GSH-Px) convert hydrogen peroxide to water and oxygen. Reduced GSH is oxidized by GSH-Px to oxidized GSH. Glutathione peroxidase also converts nitrate (a by-product of NO radicals) to nitrite. Nitrite is often used as a marker for NO activity. Hydroxyl radicals, produced from both hydrogen peroxide and NO, promote apoptosis, DNA damage,
protein carboxylation, and lipid peroxidation. Vitamin E, acting as an antioxidant, can inhibit lipid peroxidation. In turn, the resulting vitamin E radicals can be recycled by the action of vitamin C. Thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA) are important end products of lipid peroxidation. Thiobarbituric acid reactive substances measure endogenous MDA, although additional MDA might be generated in the assay as well as other products of lipid peroxidation. Figure 1 describes these potential relationships between free radicals and antioxidant defenses. Schizophrenia is also associated with immune/inflammatory abnormalities. Inflammation and oxidative stress reciprocally induce each other in a positive feedback manner (19). Functional profiling of T-lymphocytes found prominent gene expression changes pertaining to oxidative stress in minimally medicated subjects with FEP compared with control subjects (20). Although the “starting point” of inflammatory and oxidative stress abnormalities remains unclear, several hypotheses with regard to the etiopathophysiology of schizophrenia have been postulated, including activated microglia (21), lower/impaired antioxidant defenses (18), development redox dysregulation (22), and impaired GSH synthesis (23). In two previous meta-analyses in Biological Psychiatry, we found increased blood levels of pro-inflammatory cytokines, including interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (24), as well as total, CD3, and CD4 lymphocytes (25) in subjects with FEP compared with control subjects. In these studies, we found that some parameters, including blood IL-1β, IL-6, and CD4 lymphocyte levels might be state-related markers for acute psychosis, whereas blood tumor necrosis factor-α and CD56 lymphocyte levels might be trait markers for schizophrenia (24,25).

A previous systematic, quantitative review of oxidative stress markers found a significant increase in TBARS and NO but not CAT, GSH-Px, or SOD in patients with schizophrenia versus control subjects (26). However, there is considerable heterogeneity among these studies with respect to: 1) sample sources (e.g., serum, plasma, RBCs); 2) illness duration; 3) treatment setting; and 4) consideration of potential confounding factors. Meta-analysis is one approach to bring increased clarity to an area of research with significant heterogeneity (27) and thus is well-suited to the study of oxidative stress in schizophrenia. Given our previous findings of state- and trait-related markers for acute psychosis, we performed a meta-analysis of serum, plasma, and RBC oxidative stress parameters, considering the effects of clinical status, antipsychotic treatment after an acute exacerbation of psychosis, and correlations with clinical features. The primary aim was to establish the characteristic oxidative stress profile that emerges in schizophrenia and, in doing so, to integrate these findings with data on other immune/inflammatory abnormalities.

**Figure 1.** Potential relationships between free radicals and antioxidant defenses. Superoxide dismutase (SOD) catalyzes the conversion of superoxide radicals (O2•−) to hydrogen peroxide (H2O2). Both catalase (CAT) and glutathione peroxidase (GSH-Px) convert H2O2 to water (H2O) and oxygen (O2). Reduced glutathione (GSH) is oxidized by GSH-Px to oxidized glutathione (GSSG). The GSH-Px also converts nitrate (NO3•−, a by-product of nitric oxide radicals) to nitrite. Nitrite is often used as a marker for nitric oxide (NO) activity. Hydroxyl radicals (OH•), which are produced from both H2O2 and NO, promote apoptosis, DNA damage, protein carboxylation, and lipid peroxidation. Thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA) are important end products of lipid peroxidation. The TBARS measures endogenous MDA, although additional MDA might be generated in the assay.

**Methods and Materials**

**Study Selection**

Studies of oxidative stress parameters in schizophrenia were systematically searched with Medline (PubMed, National Center for Biotechnology Information, U.S. National Library of Medicine, Bethesda, Maryland), PsycInfo (via Ovid, American Psychological Association, Washington, DC), and Thomson Reuters (formerly ISI) Web of Knowledge (Science Citation Index and Social Sciences Citation Index, Thomson Reuters, Charlottesville, Virginia) in September 2012. The primary search strategy was “(oxidative stress) and (schizophrenia or psychotic disorders),” which yielded 234 articles from PubMed, 177 from PsycInfo, and 626 from Institute for Scientific Information, and the resulting matches were screened. From these sources as well as a manual review of reference lists, we identified 122 potential studies for inclusion, which are described in Table S1 in Supplement 1 (5–8,10,28–144). Most matches were excluded, because they: 1) did not present data on oxidative stress parameters; 2) were review articles; 3) were in vitro studies; 4) were genetic studies of antioxidant enzymes; 5) were animal studies; or 6) were not published in English.
The inclusion criteria were: either 1a) cross-sectional studies of oxidative stress parameters in serum, plasma, or RBCs in patients with schizophrenia or related psychotic disorders (including schizophrenia-form disorder, brief psychotic disorder, psychotic disorder not otherwise specified, delusional disorder, and schizoaffective disorder) and healthy control subjects, or 1b) longitudinal studies that assessed oxidative stress parameters in patients with an acute exacerbation of psychosis at baseline and again after a period of antipsychotic treatment for relapse; 2) clinical studies of patients clearly defined as acutely relapsed inpatients (AR), FEP patients, stable medicated outpatients (SO), or chronic inpatients (chronic IP); and 3) studies published in English. For studies that included patients with different clinical statuses (e.g., both AR and FEP), if stratified data were not presented in the manuscript, we attempted to contact study authors. The exclusion criteria were: 1) studies without a control group (except for longitudinal studies); 2) studies that did not present mean and SDs for oxidative stress parameters (after attempting to contact the study authors); 3) studies with significant overlap in study population; and 4) genetic studies related to antioxidant enzymes.

We focused on 10 oxidative stress parameters—total antioxidant status (TAS), CAT, GSH-Px, SOD, MDA, nitrile, TBARS, uric acid, vitamin C, and vitamin E—because these were measured in multiple studies. We included only studies measuring oxidative stress parameters in serum, plasma, and RBCs, because there were insufficient data for meta-analysis of parameters in other sample sources (e.g., cerebrospinal fluid, neutrophils, platelets, and postmortem brain tissue).

After independent searches, review of study methods by two authors (J.F. and B.J.M.), and attempts to contact study authors, 44 of 122 identified studies met the inclusion criteria. There was universal agreement on the included studies. Cross-sectional studies included 5 studies of AR, 19 studies of FEP, 15 studies of SO, and 12 studies of chronic IP. Five longitudinal studies assessed oxidative stress parameters in patients with an acute exacerbation of psychosis at two time points. Seventy-eight studies were excluded, due to: parameter not measured in serum, plasma, or RBCs (n = 23); clinical status not available (n = 22); measured PUFAs or insufficient data for meta-analysis (n = 14); no control group (n = 7); means and/or SDs not available (n = 6); significant study population overlap (n = 3); stratified data not available by clinical status (n = 2); and child and adolescent study population (n = 1). Each included study was assessed and assigned a “Quality Score” by one author (B.J.M.), which was independently verified by another author (J.F.). Quality scores were based on the sum of the presence or absence of consideration of the potential effects of eight factors (one point for each): age; sex; race; fasting status; socioeconomic status (SES); body mass index (BMI); smoking; and medications by either: 1) matching patients and control subjects, or 2) controlling for these variables in the analysis. Studies were given one point for medications if subjects were: 1) drug-naive FEP; 2) drug-free for a specified time period; or 3) all treated with the same antipsychotic medication. A flow chart summarizing the study selection process is presented in Figure S1 in Supplement 1.

Data Extraction and Meta-Analysis

Data were extracted (sample size, mean, and SD for schizophrenia and control subjects) for each oxidative stress parameter assessed in each study. One author (J.F.) extracted all data, which was independently verified by another author (B.J.M.). We then calculated effect size (ES) estimates (Hedges’ g) for all parameters in each study, and these data are included in Table S2 in Supplement 1. Random effects pooled ES estimates and 95% confidence intervals (CIs) were calculated with the method of DerSimonian and Laird. Random effects models yield their actual first error rate, whereas fixed effect models tend to inflate their first error rate. CIs obtained by fixed effect models are also biased, and their actual coverage rate is smaller than their nominal coverage rate (145). Meta-analysis could not be performed for oxidative stress parameters that were assessed in only a single study.

For cross-sectional studies that assessed patients with schizophrenia and control subjects at a single time point, separate meta-analyses were performed for each oxidative stress parameter by clinical status (AR, FEP, SO, or chronic IP) and sample source (serum, plasma, or RBCs). The main statistical hypothesis was that the ES for the difference between patients and control subjects for each oxidative stress parameter equals zero. In a secondary analysis, we repeated the meta-analysis procedure for cross-sectional studies stratified by whether the study matched subjects or statistically controlled for smoking. For longitudinal studies of patients with schizophrenia that measured oxidative stress parameters at baseline and endpoint after antipsychotic treatment (for either AR or FEP), separate meta-analyses were performed for each parameter by sample source. The main statistical hypothesis was that the ES for the difference between pre- and postantipsychotic treatment for each oxidative stress parameter equals zero. All tests were two-sided, and p values were considered statistically significant at the α = .05 level. The statistical analyses were performed in Stata 10.0 (StataCorp, College Station, Texas).

The meta-analysis procedure also calculates a χ² value for the heterogeneity in ES estimates, which is based on Cochran’s Q-statistic (146). Between-study heterogeneity χ² was considered significant for p < .10 (147). For oxidative stress parameters measured in 3 or more studies with significant between-study heterogeneity χ², we performed a sensitivity analysis. This was done by removing one study at a time and repeating the meta-analysis procedure for that parameter, to examine its impact on the ES estimate and heterogeneity (148).

We also extracted correlational data for oxidative stress parameters and patient clinical features including, age, age of illness onset, illness duration, and psychopathology. We recorded the direction, magnitude, and statistical significance (yes/no) of each correlation. A quantitative analysis of correlational data was not possible. We examined these data qualitatively for replicated, significant findings.

Results

Quality scores for the 44 included studies ranged from 1 to 8, with a mean score of 3.9. Figure 2 presents ES estimates with 95% CIs by clinical status. These data are also presented in tabular form in Table S3 in Supplement 1.

Cross-Sectional Studies

Acutely Relapsed Inpatients. The RBC SOD, GSH-Px, and CAT were significantly decreased in AR versus control subjects (p ≤ .01) for each, although there was significant heterogeneity in ES estimates for RBC SOD and GSH-Px. In sensitivity analyses, the heterogeneity was no longer significant, and RBC SOD and GSH-Px both remained significantly decreased after removal of one study (96 and 100, respectively).

First-Episode Psychosis. The RBC SOD and CAT (p < .01 for each) but not GSH-Px (p = .26) were significantly decreased in FEP versus control subjects. Effect sizes for RBC SOD and CAT were similar in direction and magnitude to those in AR. Plasma TBARS, MDA, and SOD were significantly increased in FEP versus control subjects, whereas plasma nitrite and uric acid were significantly decreased (p < .01 for each). Plasma and serum
TAS were significantly decreased in FEP versus control subjects ($p < .01$ for each). There was significant heterogeneity in ES estimates for all parameters in FEP except uric acid. In sensitivity analyses, the heterogeneity was no longer significant, and plasma SOD and RBC GSH-Px remained significantly increased after removal of one study (47 and 76, respectively), plasma TBARS remained significantly increased after removal of two studies (68,75). Plasma TAS and RBC CAT and SOD

---

Figure 2. Oxidative stress parameters in schizophrenia by sample source and clinical status. Effect size estimates and 95% confidence intervals (CIs) for oxidative stress parameters in cross-sectional studies of acute relapse of psychosis (A) and drug-naïve first-episode psychosis (C), stable medicated outpatients (D), and chronic inpatients (F) versus control subjects are represented by gray bars and black error bars in each panel, respectively. Effect size estimates and 95% CIs for oxidative stress parameters in cross-sectional studies of patients with schizophrenia versus control subjects stratified by smoking status (E) are represented by gray bars and black error bars, respectively. Effect size estimates and 95% CIs for changes in oxidative stress parameters in longitudinal studies after antipsychotic treatment for an acute exacerbation of psychosis (B) are represented by gray bars and black error bars, respectively. Positive effect sizes (bars going to the right) indicate that the parameter was higher in schizophrenia than control subjects (A, C–F) or that the parameter decreased after antipsychotic treatment for acute psychosis (B). Negative effect sizes (bars going to the left) indicate that levels were higher in control subjects than in patients with schizophrenia (A, C–F) or that the parameter increased after antipsychotic treatment for acute psychosis (B). Error bars that exclude an effect size of 0 are significant at the $p < .05$ level. *Effect size is for studies that did not match/control for smoking. All other effect sizes in this figure are for studies that matched/controlled for smoking. Abbreviations as in Figure 1.
remained significantly decreased after removal of one study (26 and 56, respectively).

**Stable Medicated Outpatients.** The RBC SOD was significantly decreased \((p < .01)\), and RBC CAT was significantly increased \((p < .01)\) in SO versus control subjects. There was no difference in RBC GSH-Px in SO versus control subjects \((p = .82)\). Plasma nitrite was significantly increased \((p < .01)\) in SO versus control subjects. Serum TBARS was significantly increased \((p < .01)\), whereas plasma TBARS was nonsignificantly increased \((p = .59)\) in SO versus control subjects. Serum SOD was significantly increased in SO versus control subjects \((p < .01)\). There was significant heterogeneity in ES estimates for all parameters in SO except serum SOD. In sensitivity analyses, the heterogeneity was no longer significant, and serum TBARS remained significantly increased after removal of one study \((73)\). In all other sensitivity analyses, the heterogeneity remained significant after removing each single study as well as all combinations of two studies.

**Chronic Inpatients.** The RBC and plasma CAT and GSH-Px were significantly decreased, and plasma MDA and SOD were significantly increased, in chronic IP versus control subjects \((p < .01\) for each). There was no difference in RBC SOD \((p = .77)\) plasma TBARS \((p = .59)\), or plasma uric acid \((p = .15)\) in chronic IP versus control subjects. In a sensitivity analysis, the heterogeneity was no longer significant, and plasma GSH-Px and SOD remained significantly decreased after removal of one study \((31)\). Sensitivity analyses were not possible for other parameters.

**Secondary Analysis Stratified by Smoking.** Figure 2 also includes ES estimates with 95% CIs by smoking status. These data are also presented in tabular form in Table S3 in Supplement 1. In studies that matched/controlled for smoking, RBC SOD, GSH-Px, and CAT were significantly decreased in AR versus control subjects \((p < .01\) for each). Plasma uric acid was significantly decreased in FEP versus control subjects \((p < .01)\) in studies that matched/controlled for smoking. Plasma GSH-Px and SOD were significantly decreased, and plasma MDA was significantly increased, in chronic IP versus control subjects \((p < .01\) for each) in studies that matched/controlled for smoking. By contrast, in studies that did not consider smoking status plasma SOD was nonsignificantly increased in chronic IP versus control subjects \((p = .13)\). There was no difference in plasma uric acid in chronic IP versus control subjects \((p = .15)\) in studies that matched/controlled for smoking. There was a trend for increased plasma CAT in studies that matched/controlled for smoking \((p = .06)\), whereas plasma CAT was significantly decreased in all studies of chronic IP versus control subjects \((p < .01)\). In studies that matched/controlled for smoking, plasma nitrite was significantly increased in SO versus control subjects \((p < .01)\).

**Longitudinal Studies**

Figure 2 and Table S3 in Supplement 1 also present ES estimates with 95% CIs for changes in oxidative stress parameters after antipsychotic treatment for an acute exacerbation of psychosis. There was a significant increase in serum TAS \((p < .01)\) after a mean of 2.5 months antipsychotic treatment for acute psychosis. Although there was significant heterogeneity in the ES estimate, both individual studies \((26,36)\) reported significant increases in serum TAS. In one study \((32)\), all subjects were treated with olanzapine for 2 months. In the other study \((42)\), all but 2 subjects were treated with either olanzapine or risperidone for 3 months.

**Correlations with Clinical Features.** Only 12 of 44 (27%) studies included in the meta-analysis provided correlative data. There were no replicated, significant correlations between oxidative stress parameters and any clinical features.

**Discussion**

Our findings suggest that oxidative stress parameters in schizophrenia might vary with clinical status. Blood TAS seemed to be a state marker, because levels in cross-sectional studies in FEP were significantly decreased and significantly increased in longitudinal studies of antipsychotic treatment for acute psychosis. The RBC catalase and plasma nitrite also seemed to be state-related markers, as levels in cross-sectional studies were significantly decreased in FEP and increased in SO. Likewise, plasma SOD levels in cross-sectional studies were significantly increased in FEP and decreased in SO. In contrast, RBC SOD seemed to be a trait marker for schizophrenia, as levels in cross-sectional studies were significantly decreased in AR, FEP, and SO.

An important strength of our study is that we considered potential effects of sample source, clinical status, smoking, and antipsychotic treatment after acute psychosis. A previous meta-analysis found significant alterations in levels of NO but not CAT, GSH-Px, and SOD in patients with schizophrenia versus control subjects \((26)\). Our analysis differed from this study in several ways. First, we considered effects of sample source (e.g., in FEP, levels of SOD were increased in plasma but decreased in RBC). Secondly, we considered effects of clinical status on oxidative stress parameters. For example, the previous meta-analysis reported a significant increase in NO in schizophrenia, whereas we found significantly decreased plasma nitrite in FEP (vs. increased levels in SO). Another meta-analysis found significantly increased MDA levels in schizophrenia, consistent with our results, but did not stratify by sample source \((149)\). Third, we investigated changes in oxidative stress parameters after antipsychotic treatment for an acute exacerbation of psychosis. Lastly, in a secondary analysis, we considered potential effects of smoking.

There are several limitations of the present study. Results for many parameters should be interpreted with caution in light of small numbers of studies and subjects, between-study heterogeneity, and different assay methodologies. Many factors likely contribute to the observed heterogeneity in oxidative stress parameters, including age, gender, race, ethnicity, BMI, smoking, dietary habits, medication effects, sampling effects of different stages of disease progression, and different clinical course of illness. On the basis of available data, it was also not possible to evaluate effects of specific antipsychotic agents on individual oxidative stress parameters, because most studies included subjects treated with a variety of agents. Treatment with atypical versus typical antipsychotics as well as the duration of antipsychotic treatment might have differential effects on oxidative stress parameters. However, our findings in drug-naive FEP suggest an association between schizophrenia and oxidative stress that might be independent of antipsychotics.

Furthermore, many studies did not control for aforementioned potential confounding factors that could account for differences in oxidative stress parameters \((150–152)\). For example, effects of age and gender were considered in 97% and 87% of studies, respectively. One study found a gender-specific difference in vitamin E levels \((44)\), but a subanalysis was not possible due to the limited number of studies that included gender-stratified data. By contrast, subjects were fasting at the time of blood collection in only 55% of studies. Even fewer studies considered potential effects of SES (21%) and BMI (8%). Genetic factors associated with race or ethnicity might also play
a role in the observed associations. We found evidence that RBC SOD might be a trait marker for schizophrenia. A Turkish study found that a polymorphism in the gene for SOD was associated with increased risk of schizophrenia (153). The effect of this polymorphism on schizophrenia risk in other populations as well as the potential effect on RBC SOD levels is unknown. However, it is important to note that a number of well-controlled studies found significant alterations in oxidative stress parameters, suggesting that findings are not due to residual confounding (39,73,94,97,134,139).

Another limitation of our study is that alterations of oxidative stress parameters in the peripheral blood might not be mirrored in the central nervous system and do not necessarily relate to the same pathophysiological mechanisms. Importantly, however, several studies found evidence for central nervous system oxidative stress/impaired antioxidant defenses, including in vivo MRS studies of phospholipids (9) and GSH (7,76,123) as well as postmortem studies of the GSH redox system (8).

We excluded a number of studies because either the patient clinical status or summary data were not available. Some of these studies would have otherwise been included in the meta-analysis, and their influence on the results is uncertain. Several elegant, well-controlled studies by Yao et al. (128–130) were not included, because the clinical status of the subjects was not directly comparable to other studies. In these studies, SO were hospitalized and treated with haloperidol for 3 months, which was then withdrawn for up to 3 months and replaced with placebo. One of these studies found significantly decreased plasma TAS in schizophrenia versus control subjects (128), consistent with our results.

Furthermore, our results seem to be internally consistent, as would be predicted by Figure 1 (i.e., the observed decreased SOD activity should result in increased superoxide radicals). In the setting of the observed decreased GSH-Px activity, superoxide radicals would be shunted toward hydroxyl radical production and away from nitrite production (we found decreased plasma nitrite). The observed decreased CAT and GSH-Px activity would also shunt the conversion of hydrogen peroxide from water and oxygen toward hydroxyl radical production. Increase hydroxyl radicals would result in increased lipid peroxidation, and we found increased TBARS and MDA. We also found a significant decrease in TAS, which is consistent with impaired antioxidant defenses.

We previously found—similar to the observed pattern of results for oxidative stress parameters in this study—an abnormal blood cytokine and lymphocyte parameters in schizophrenia that varied with clinical status, with increased pro-inflammatory cytokines and CD3 and CD4 lymphocytes in acute exacerbations of psychosis (24,25). A recent meta-analysis found significantly decreased levels of RBC membrane PUFAs—including arachidonic, docosahexaenoic, and docosapentaenoic acid—in subjects with FEP compared with control subjects, which is also consistent with free radical-mediated damage due to impaired antioxidant defenses (154). Taken together, these findings provide further support for important potential inter-relationships between immune function, oxidative stress, and membrane PUFAs in the pathophysiology of schizophrenia (Figure 3).

Our findings are of importance, because acute relapse of psychosis is common and associated with adverse outcomes (155–157). More longitudinal studies are needed to evaluate how oxidative stress parameters vary over the clinical course and different stages of disease progression in schizophrenia. Repeated findings for state-related markers for acute psychosis would support their utility as a potential biomarker to inform relapse prevention strategies and monitor response to treatment. It is critical that future studies control for factors known to influence...
oxidative stress parameters (150–152). Studies are also needed that simultaneously measure blood immune/inflammatory and oxidative stress parameters, which could provide stronger clues with regard to the “starting point” of these abnormalities. Furthermore, correlations between oxidative stress parameters and clinical features should be routinely assessed, which could inform on potential causal mechanisms of psychopathology. Replicated findings might suggest novel antioxidant treatment strategies. Ultimately, oxidative stress informs on the etiopathophysiology of schizophrenia and might serve as a biomarker and therapeutic target in the clinical course of the disorder (158).

We wish to thank Linda H. Young and Billy P. Houke for assistance with articles. We also wish to thank Alin Ciobica, Clarissa Gama, Masanari Ikowaga, Yong-Ku Kim, Aleksandra Nikolic-Kocik, Ravinder Reddy, Venkatasubramanian, Jeffrey Yao, and Shane Yang Zhang, for sharing summary data and/or clarifying information.

Mr. Flatow reports no biomedical financial interests or potential conflicts of interest. Dr. Buckley received grant/research support from the National Institute of Mental Health, Janssen Pharmaceuticals, Pfizer, and Sunovion and is a consultant (honorarium/expenses) for the National Institute of Mental Health. In the past 3 years, Dr. Miller has received grant support from the National Institute of Mental Health (1K23MH098014-01), the Georgia Regents University Intramural Scientist Training Program, the GRU Brain & Behavior and Immunotherapy Discovery Institutes, the University of Oulu (Finland), the Thule Institute of the University of Oulu, and Oy H. Lundbeck Ab; research support from the National Institutes of Health Clinical Loan Repayment Program; consultancy fees for surveys from Medefied Europe and Plaza Research, on behalf of Genethon/Roche; speaker fees for grand rounds lectures consultancy fees for surveys from Medefied Europe and Plaza Research, on behalf of Genethon/Roche; speaker fees for grand rounds lectures on behalf of Genethon/Roche; speaker fees for grand rounds lectures; and risperidone action. Mr. Flatow reports no biomedical financial interests or potential conflicts of interest.

Supplementary material cited in this article is available online at http://dx.doi.org/10.1016/j.biopsych.2013.03.018.


www.sobp.org/journal


